Tekla Capital Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Tekla Capital Management’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-37,700	Closed	-$561K	–	204
2019 Q2	$561K	Sell	37,700 -37,700	-50%	-$681K	0.02%	181
2019 Q1	$1.87M	Hold	75,400	–	–	0.08%	134
2018 Q4	$1.35M	Hold	75,400	–	–	0.06%	146
2018 Q3	$2.21M	Hold	75,400	–	–	0.08%	147
2018 Q2	$3.43M	Hold	75,400	–	–	0.13%	108
2018 Q1	$3.98M	Hold	75,400	–	–	0.15%	102
2017 Q4	$5.13M	Hold	75,400	–	–	0.2%	89
2017 Q3	$6.21M	Sell	75,400 -75,400	-50%	-$5.98M	0.22%	78
2017 Q2	$14.1M	Buy	+150,800	New	+$9.23M	0.52%	41
2015 Q1	–	Sell	-51	Closed	-$3K	–	125
2014 Q4	$3K	Sell	51 -104,000	-100%	-$5.47M	﹤0.01%	96
2014 Q3	$4.72M	Buy	104,051 +56,687	+120%	+$2.37M	0.22%	81
2014 Q2	$1.96M	Hold	47,364	–	–	0.18%	57
2014 Q1	$3.28M	Buy	47,364 +14,706	+45%	+$1.08M	0.33%	51
2013 Q4	$1.97M	Buy	32,658 +9,971	+44%	+$542K	0.21%	48
2013 Q3	$1.38M	Buy	+22,687	New	+$1.61M	0.15%	58

Other funds holding CLVS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

ECP

Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Tekla Capital Management's CLVS Position: Q3 2019 in Review

Tekla Capital Management sold out of Clovis Oncology, Inc. (CLVS) in Q3 2019, closing a stake of 37,700 shares — an estimated $561K sold.

Tekla Capital Management first reported a position in CLVS in Q3 2013 and held it in 15 quarters. The position peaked at $14.1M in Q2 2017. 153 funds tracked by Wall St. Rank hold CLVS as of Q3 2019.

Tekla Capital Management reported no remaining Clovis Oncology, Inc. position as of Q3 2019 after selling out during the quarter.
Tekla Capital Management sold 37,700 Clovis Oncology, Inc. shares in Q3 2019, an estimated $561K.
Tekla Capital Management first reported a position in Clovis Oncology, Inc. in Q3 2013 and held it in 15 quarters.
Tekla Capital Management's Clovis Oncology, Inc. position peaked at $14.1M in Q2 2017.
153 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2019.

Based on Tekla Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.